Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster immunogenicity and antibody persistence study of DTPa-IPV/Hib priming in healthy Chinese toddlers
2012-003324-20Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acthib + dpt-ipv, inactivated poliovirus vaccine and diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more, sponsored by GSK. Primary endpoint: Pre-booster antibody persistence and seroprotection/seropositivity.
02
Drugs
acthib + dpt-ipvinactivated poliovirus vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2012-003324-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003324-20.